[to the editor]{.smallcaps}: With great interest we read the article by Yousaf et al. ([@B5]) recently published in your journal. This seems to be the first publication to raise the issue of association of COVID-19 and syndrome of inappropriate antidiuretic hormone secretion (SIADH). In fact, such an association should be quite expected, as according to one of the first reports on the COVID-19 outcomes, the majority (71%) of critically ill adult patients with SARS-CoV-2 pneumonia required mechanical ventilation. Critically ill patients of this center had a high mortality (61.5%) and those who did not survive were more likely to have received mechanical ventilation (94% vs. 35%) ([@B4]). Positive pressure ventilation (PPV) is a well-known reason of SIADH and hyponatremia development ([@B1]), probably due to nonosmotic stimulation of antidiuretic hormone (ADH) secretion, as pulmonary venous baroreceptors respond to a reduction in effective blood volume. Unfortunately, the authors of articles indicating an association between COVID-19 and plasma sodium depletion ([@B2]) or who provide advice on the level of PPV use in the treatment of severe acute respiratory distress syndrome from COVID-19 ([@B3]) do not mention the possibility of developing SIADH and methods of its treatment. Yousaf et al. ([@B5]) does not mention the possibility of developing SIADH in patients with COVID-19 in the case of treatment with PPV. Moreover, the authors propose a mechanism for SIADH in COVID-19 infection that not only does not mention PPV but contains some unusual statements. In particular, the authors claim that *decreased* intravascular osmolality leads to osmoreceptor activation and ADH secretion (see Fig. 1). It is known that the stimulus to ADH secretion is an *increase* in intravascular osmolality ([@B1]).

Thus, the development of SIADH may be one of the reasons for unsatisfactory treatment of COVID-19 with PPV, which should be considered during such treatment. In particular, this may include careful monitoring of sodium levels and fluid restriction in case of SIADH detection.
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